search

Active clinical trials for "Pancytopenia"

Results 61-70 of 87

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases...

Bone Marrow Failure SyndromesImmunodeficiencies1 more

This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from mismatched donors. There are two conditioning regimens depending upon patient diagnosis and age.

Completed8 enrollment criteria

Stem Cell Transplant for Bone Marrow Failure Syndromes

Diamond-Blackfan AnemiaKostmann's Neutropenia1 more

The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.

Completed17 enrollment criteria

Gene Therapy for the Treatment of Fanconi's Anemia Type C

Fanconi's AnemiaPancytopenia

Fanconi's Anemia is an inherited disorder that can produce bone marrow failure. In addition, some patients with Fanconi's anemia have physical defects usually involving the skeleton and kidneys. The major problem for most patients is aplastic anemia, the blood counts for red blood cells, white blood cells, and platelets are low because the bone marrow fails to produce these cells. Some patients with Fanconi's anemia can develop leukemia or cancers of other organs. Many laboratory studies have suggested that Fanconi's anemia is caused by an inherited defect in the ability of cells to repair DNA. Recently, the gene for one of the four types of Fanconi's anemia, type C, has been identified. It is known that this gene is defective in patients with Fanconi's anemia type C. Researchers have conducted laboratory studies that suggest Fanconi's anemia type C may be treatable with gene therapy. Gene therapy works by placing a normal gene into the cells of patients with abnormal genes responsible for Fanconi's anemia type C. After the normal gene is in place, new normal cells can develop and grow. Drugs can be given to these patients kill the remaining abnormal cells. The new cells containing normal genes and will not be harmed by these drugs. The purpose of this study is to test whether researchers can safely place the normal Fanconi's anemia type C gene into cells of patients with the disease. The gene will be placed into special cells in the bone marrow called stem cells. These stem cells are responsible for producing new red blood cells, white blood cells, and platelets.

Completed25 enrollment criteria

Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

Malignant Diseases (ieLeukemia4 more

T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).

Completed9 enrollment criteria

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT

Bone Marrow Failure Syndromes

Randomized comparison of cyclophosphamide versus reduced-dose cyclophosphamide plus fludarabine in addition to anti-thymocyte globulin for the conditioning therapy in allogeneic hematopoietic cell transplantation for bone marrow failure syndrome.

Completed12 enrollment criteria

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With...

Severe Aplastic AnemiaBone Marrow Failure Syndromes

Our primary objective is to determine if it is feasible for SAA patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide with partially HLA-mismatched donors.

Completed22 enrollment criteria

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

Pancytopenia Due to Chemotherapy

The goal of this clinical research study is to find out if rhIL-11(Interleukin 11) may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT(cyclophosphamide+Cytosine arabinoside+mercaptopurine,7d) therapy.

Completed5 enrollment criteria

Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell...

Precursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia6 more

The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell grafts.

Completed7 enrollment criteria

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

AnemiaSickle Cell6 more

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.

Withdrawn39 enrollment criteria

Spectrum of Hematological Disorders in Pediatrics

Pancytopenia

To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year

Not yet recruiting2 enrollment criteria
1...6789

Need Help? Contact our team!


We'll reach out to this number within 24 hrs